With reference to point no. 2 of Annexure 1 of letter nos. NLL/CS/2024-438 dated November 22, 2024, and NLL/CS/2024-476 dated April 04, 2025, vide which the Company had informed pending Litigation(s) as required under Regulation 30 of the LODR Regulations. Pursuant to : Regulation 30 of the Securities and Exchange of Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, and as amended by Circular dated March 28, 2025, Nectar Lifesciences has informed that it enclosed necessary disclosures in prescribed format for details/ updation of Litigation and/ or orders passed by any regulatory authority or judicial body as per Annexure-A.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1679.85 |
| Dr. Reddys Lab | 1333.05 |
| Cipla | 1305.85 |
| Zydus Lifesciences | 947.10 |
| Lupin | 2340.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: